Lifecore Biomedical Q2 2026: Results, Reaffirmed Guidance, and the Road to 2029
LFCR sits 25% above its 52-week low of $3.625.
Summary
Lifecore Biomedical posted Q2 2026 revenue of $34.2M and a net loss of $6.2M, reaffirmed its full‑year guidance, and detailed a long‑term plan targeting 12% revenue CAGR and >25% Adjusted EBITDA margins by 2029, supported by a late‑stage pipeline and an expected demand inflection from its largest customer beginning in 2027.
Key Events · Earnings and Guidance · LFCR
-
Q2 2026 Financial Results
Revenue came in at $34.2M, down 6.2% year‑over‑year, with a net loss of $6.2M ($0.19/share) and Adjusted EBITDA of $8.6M, a 5.3% decline. For the first six months, revenue totaled $57.4M — a 19.9% drop — and the net loss widened to $21.1M ($0.61/share).
-
2026 Guidance Reaffirmed
Management reiterated full‑year 2026 revenue of $120–$125M and Adjusted EBITDA of $20.5–$25M, implying a significant ramp in the second half.
-
Long-Term Growth Targets
An investor presentation outlined targets of 12% revenue CAGR and >25% Adjusted EBITDA margins by year‑end 2029, driven by expansion of the existing commercial business, portfolio commercialization, and new business wins.
-
Largest Customer Demand Inflection
Contractual fill finish demand from the largest customer is projected to double in 2027 versus 2026 and grow more than 200% by 2028, with potential upside to contractual minimums.
Analysis · LFCR · Life Sciences
While Q2 results show revenue still declining and net losses persisting, the reaffirmed 2026 guidance and a new investor presentation lay out a concrete path to 12% revenue CAGR and >25% Adjusted EBITDA margins by 2029. The story hinges on a sharp inflection in 2027, when fill finish demand from the largest customer is set to double versus 2026 and 11 potential product launches from a late-stage pipeline could add $150M–$200M in incremental commercial revenue. Near‑term financials remain weak, but the long‑term narrative now comes with specific milestones investors can track. At $4.52 per share and a $163M market cap, the stock reflects deep skepticism — this update either validates the turnaround thesis or highlights the execution risk.
At the time of this filing, LFCR was trading at $4.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $163.2M. The 52-week trading range was $3.63 to $8.98. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.